financetom
Business
financetom
/
Business
/
V2X Lands $170 Million DEA Contract To Combat Drug Trafficking; Stock Gains
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
V2X Lands $170 Million DEA Contract To Combat Drug Trafficking; Stock Gains
Dec 30, 2024 6:48 AM

V2X, Inc. ( VVX ) shares are trading higher premarket on Monday. The company secured a $170 million contract to support the Drug Enforcement Administration’s (DEA) fleet of over 100 aircraft.

This award highlights V2X’s dedication to advancing the DEA’s mission in combating drug trafficking and safeguarding national security.

Jeremy C. Wensinger, President and CEO of V2X, said, “V2X has consistently demonstrated a complete understanding of the DEA’s mission, and the flexibility required to support its special mission aircraft and pilot development.”

“This award reflects the trust placed in our team to deliver high-impact solutions that empower the DEA to combat drug trafficking and safeguard national security.”

Earlier this month, V2X formed a strategic joint venture with Parsons Corporation ( PSN ) to pursue the National Science Foundation’s Antarctica Science and Engineering Support Contract (ASESC) with a ceiling value of $8 billion.

This joint venture will provide world-class scientific research support for the U.S. Antarctic Program over the next two decades.

Recently, V2X opened its new corporate headquarters in Reston, Virginia. The new location supports V2X’s presence in a region that serves as a defense, technology, and aerospace industry hub and will advance V2X’s missions.

Price Action: VVX shares are up 4.15% at $48.93 premarket at the last check Monday.

Read Next:

Warren Buffett Was Once Praised By Vitalik Buterin As An ‘Excellent Charity Allocator, If You Invested $1,000 In Ethereum At That Moment, Here’s How Much You’d Have Today

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
InterDigital Starts Patent Infringement Litigation Against Amazon
InterDigital Starts Patent Infringement Litigation Against Amazon
Nov 10, 2025
05:46 AM EST, 11/10/2025 (MT Newswires) -- InterDigital (IDCC) said Monday it initiated patent infringement lawsuits against Amazon ( AMZN ) in the US, Brazil and Germany. The company said Amazon ( AMZN ) devices and Prime Video infringe on InterDigital's technology related to video content compression and quality enhancement. Amazon ( AMZN ) did not immediately respond to MT...
E.l.f. Beauty Says e.l.f.iverse Launches at ULTA Beauty in Mexico; Shares Up Pre-Bell
E.l.f. Beauty Says e.l.f.iverse Launches at ULTA Beauty in Mexico; Shares Up Pre-Bell
Nov 10, 2025
05:52 AM EST, 11/10/2025 (MT Newswires) -- E.l.f. Beauty (ELF) said Monday it has officially launched its e.l.f.iverse at ULTA Beauty ( ULTA ) in Mexico. The company said e.l.f. Cosmetics and e.l.f. SKIN products will now be available in all ULTA Beauty ( ULTA ) stores across the country as well as on the retailer's e-commerce platform. E.l.f. Beauty...
Cargojet Renews Normal Course Issuer Bid for Voting Shares
Cargojet Renews Normal Course Issuer Bid for Voting Shares
Nov 10, 2025
05:55 AM EST, 11/10/2025 (MT Newswires) -- Cargojet ( CGJTF ) , which rose 2.5% on Friday, later that day said it has received approval from the Toronto Stock Exchange to renew its normal course issuer bid for common voting shares and variable voting shares. The NCIB is scheduled to run from Nov. 11, 2025, to Nov. 10, 2026. Purchases...
Merck's Phase 3 Trial of Enlicitide Decanoate in Heterozygous Familial Hypercholesterolemia Achieves Primary Endpoint
Merck's Phase 3 Trial of Enlicitide Decanoate in Heterozygous Familial Hypercholesterolemia Achieves Primary Endpoint
Nov 10, 2025
05:54 AM EST, 11/10/2025 (MT Newswires) -- Merck ( MRK ) said Sunday that a phase 3 study of its elicitide decanoate product candidate achieved its primary endpoint, demonstrating statistically significant reduction in low-density lipoprotein cholesterol, or LDL-C, in adult patients with heterozygous familial hypercholesterolemia. The company said enlicitide led to a clinically meaningful LDL-C reduction of 59.4% compared with...
Copyright 2023-2026 - www.financetom.com All Rights Reserved